董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Firdaus Jal Dastoor | 男 | Director | 70 | 5.96万美元 | 未持股 | 2023-11-13 |
| Roger Kornberg | 男 | Director | 75 | 5.96万美元 | 未持股 | 2023-11-13 |
| Jeffrey F. Eisenberg | 男 | Chief Executive Officer and Director | 57 | 63.28万美元 | 未持股 | 2023-11-13 |
| Dmitry Genkin | 男 | Director | 54 | 未披露 | 未持股 | 2023-11-13 |
| Moshe Mizrahy | 男 | Director | 70 | 未披露 | 未持股 | 2023-11-13 |
| Grigory Borisenko | 男 | Director | 54 | 5.96万美元 | 未持股 | 2023-11-13 |
| James Callaway | 男 | Director | 67 | 5.96万美元 | 未持股 | 2023-11-13 |
| Alexey Vinogradov | 男 | Director | 53 | 5.96万美元 | 未持股 | 2023-11-13 |
| Moshe Mizrahy | 男 | Director | 70 | 未披露 | 未持股 | 2023-11-13 |
| Adam Logal | 男 | Chairman of the Board | 45 | 5.96万美元 | 未持股 | 2023-11-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey F. Eisenberg | 男 | Chief Executive Officer and Director | 57 | 63.28万美元 | 未持股 | 2023-11-13 |
| Curtis Lockshin | 男 | Chief Scientific Officer | 63 | 47.04万美元 | 未持股 | 2023-11-13 |
| James Parslow | 男 | Chief Financial Officer and Corporate Secretary | 57 | 47.40万美元 | 未持股 | 2023-11-13 |
董事简历
中英对照 | 中文 | 英文- Firdaus Jal Dastoor
-
Firdaus Jal Dastoor自2014年1月起担任公司董事，符合公司收购Xenetic U.K。 的条例要求。Dastoor于2007年7月被任命为Xenetic U.K。 非执行董事。他自2008年起担任The Institute of Company Secretaries of India研究员。他一直担任Poonawalla Group公司秘书到1994年。后来他接手业务开发战略和运营任务，包括Serum Institute, Eureka Finvest Pvt, Ltd, EagleBurgmann India Pvt, Ltd. And PPCE Pvt, Ltd.Dastoor现任多个公司（工程产品、生命科学和生物技术、国际贸易、金融服务和质量标准认证）董事。如今他担任Poonawalla Group of Companies集团主管，负责金融和企业事务。
Firdaus Jal Dastoor,was initially appointed as a member of Xenetic Biosciences, Inc. Board in January 2014 pursuant to terms of the agreement of Xenetic Biosciences, Inc. acquisition of Xenetic U.K. He has been employed by the Cyrus Poonawalla Group, a conglomerate in India with interests in horse breeding, biotech and life sciences, and financial services, in business development strategies and operational roles since October 1981. Mr. Dastoor is currently a Group Director in charge of Finance and Corporate Affairs and Company Secretary of the Serum Institute of India Private Limited at the Cyrus Poonawalla Group. He has been a Fellow Member of The Institute of Company Secretaries of India since 1990. Mr. Dastoor is on the board of several private companies operating in the fields of life sciences and biotech, international trade, financial services and quality standards certifications. Mr. Dastoor received a B.A. in Commerce from the University of Poona. - Firdaus Jal Dastoor自2014年1月起担任公司董事，符合公司收购Xenetic U.K。 的条例要求。Dastoor于2007年7月被任命为Xenetic U.K。 非执行董事。他自2008年起担任The Institute of Company Secretaries of India研究员。他一直担任Poonawalla Group公司秘书到1994年。后来他接手业务开发战略和运营任务，包括Serum Institute, Eureka Finvest Pvt, Ltd, EagleBurgmann India Pvt, Ltd. And PPCE Pvt, Ltd.Dastoor现任多个公司（工程产品、生命科学和生物技术、国际贸易、金融服务和质量标准认证）董事。如今他担任Poonawalla Group of Companies集团主管，负责金融和企业事务。
- Firdaus Jal Dastoor,was initially appointed as a member of Xenetic Biosciences, Inc. Board in January 2014 pursuant to terms of the agreement of Xenetic Biosciences, Inc. acquisition of Xenetic U.K. He has been employed by the Cyrus Poonawalla Group, a conglomerate in India with interests in horse breeding, biotech and life sciences, and financial services, in business development strategies and operational roles since October 1981. Mr. Dastoor is currently a Group Director in charge of Finance and Corporate Affairs and Company Secretary of the Serum Institute of India Private Limited at the Cyrus Poonawalla Group. He has been a Fellow Member of The Institute of Company Secretaries of India since 1990. Mr. Dastoor is on the board of several private companies operating in the fields of life sciences and biotech, international trade, financial services and quality standards certifications. Mr. Dastoor received a B.A. in Commerce from the University of Poona.
- Roger Kornberg
-
Roger Kornberg自2016年2月起担任公司董事。Kornberg是U.S. National Academy of Sciences成员；Stanford University结构生物学专业医学Winzer教授。他于1967年获得Harvard University化学学士学位；1972年获得Stanford化学物理学博士学位。他是英国坎布里奇Laboratory of Molecular Biology博士后研究员；1976年成为Harvard Medical School生物化学助理教授；1978年成为Stanford Medical School结构生物学教授。2006年Kornberg被授予诺贝尔化学奖，因其对真核基因转录（DNA被复制到RNA的过程）微生物的研究而获此殊荣。Kornberg还是多个奖项的获得者，包括2001年Welch Prize（美国化学领域最高奖项）；2002年Leopald Mayer Prize（法官生物医疗科学领域最高奖项）。
Roger Kornberg,has served as a member of Xenetic Biosciences, Inc. Board since February 2016. Dr. Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University. He earned his B.S. in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972. He became a postdoctoral fellow at the Laboratory of Molecular Biology in Cambridge, England and then an assistant professor of biological chemistry at Harvard Medical School in 1976, before moving to his present position as professor of structural biology at Stanford Medical School in 1978. In 2006, Dr. Kornberg was awarded the Nobel Prize in Chemistry in recognition for his studies of the molecular basis of Eukaryotic Transcription, the process by which DNA is copied to RNA. Dr. Kornberg is also the recipient of several awards, including the 2001 Welch Prize, the highest award granted in the field of chemistry in the United States, and the 2002 Leopald Mayer Prize, the highest award granted in the field of biomedical sciences from the French Academy of Sciences. Dr. Kornberg has served as a director of Cocrystal Pharma, Inc. (NasdaqCM: COCP) since April 2020. - Roger Kornberg自2016年2月起担任公司董事。Kornberg是U.S. National Academy of Sciences成员；Stanford University结构生物学专业医学Winzer教授。他于1967年获得Harvard University化学学士学位；1972年获得Stanford化学物理学博士学位。他是英国坎布里奇Laboratory of Molecular Biology博士后研究员；1976年成为Harvard Medical School生物化学助理教授；1978年成为Stanford Medical School结构生物学教授。2006年Kornberg被授予诺贝尔化学奖，因其对真核基因转录（DNA被复制到RNA的过程）微生物的研究而获此殊荣。Kornberg还是多个奖项的获得者，包括2001年Welch Prize（美国化学领域最高奖项）；2002年Leopald Mayer Prize（法官生物医疗科学领域最高奖项）。
- Roger Kornberg,has served as a member of Xenetic Biosciences, Inc. Board since February 2016. Dr. Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University. He earned his B.S. in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972. He became a postdoctoral fellow at the Laboratory of Molecular Biology in Cambridge, England and then an assistant professor of biological chemistry at Harvard Medical School in 1976, before moving to his present position as professor of structural biology at Stanford Medical School in 1978. In 2006, Dr. Kornberg was awarded the Nobel Prize in Chemistry in recognition for his studies of the molecular basis of Eukaryotic Transcription, the process by which DNA is copied to RNA. Dr. Kornberg is also the recipient of several awards, including the 2001 Welch Prize, the highest award granted in the field of chemistry in the United States, and the 2002 Leopald Mayer Prize, the highest award granted in the field of biomedical sciences from the French Academy of Sciences. Dr. Kornberg has served as a director of Cocrystal Pharma, Inc. (NasdaqCM: COCP) since April 2020.
- Jeffrey F. Eisenberg
-
Jeffrey F. Eisenberg自2016年12月2日起担任首席运营官，于2017年10月26日被任命为Xenetic Biosciences, Inc.首席执行官，并自2016年7月起担任Xenetic Biosciences, Inc.董事会成员。Eisenberg先生以前曾在久光制药公司的子公司诺文制药公司（“诺文”）工作，在那里他担任过越来越多的职务，最近在2009-2016年期间担任诺文公司总裁、首席执行官和董事会成员。Eisenberg先生此前于2016年2月起担任Mabvax Therapeutics Holdings独立董事，至2018年7月辞职。Eisenberg先生在哥伦比亚大学法学院获得法学博士学位，在宾夕法尼亚大学沃顿商学院获得经济学学士学位。
Jeffrey F. Eisenberg,was appointed Xenetic Biosciences, Inc. Chief Executive Officer on October 26, 2017, after serving as Chief Operating Officer since December 2, 2016, and has served as a member of Xenetic Biosciences, Inc. Board since July 2016. Mr. Eisenberg previously worked at Noven Pharmaceuticals, Inc. ("Noven"), a subsidiary of Hisamitsu Pharmaceutical, Inc., where he held various positions of increasing responsibility, most recently serving from 2009-2016 as Noven's president, chief executive officer and as a member of its board of directors. Mr. Eisenberg previously served as an independent director for Mabvax Therapeutics Holdings, Inc. from February 2016 until his resignation in July 2018. Mr. Eisenberg obtained his J.D. at Columbia University Law School and a B.S. in Economics from the Wharton School, University of Pennsylvania. - Jeffrey F. Eisenberg自2016年12月2日起担任首席运营官，于2017年10月26日被任命为Xenetic Biosciences, Inc.首席执行官，并自2016年7月起担任Xenetic Biosciences, Inc.董事会成员。Eisenberg先生以前曾在久光制药公司的子公司诺文制药公司（“诺文”）工作，在那里他担任过越来越多的职务，最近在2009-2016年期间担任诺文公司总裁、首席执行官和董事会成员。Eisenberg先生此前于2016年2月起担任Mabvax Therapeutics Holdings独立董事，至2018年7月辞职。Eisenberg先生在哥伦比亚大学法学院获得法学博士学位，在宾夕法尼亚大学沃顿商学院获得经济学学士学位。
- Jeffrey F. Eisenberg,was appointed Xenetic Biosciences, Inc. Chief Executive Officer on October 26, 2017, after serving as Chief Operating Officer since December 2, 2016, and has served as a member of Xenetic Biosciences, Inc. Board since July 2016. Mr. Eisenberg previously worked at Noven Pharmaceuticals, Inc. ("Noven"), a subsidiary of Hisamitsu Pharmaceutical, Inc., where he held various positions of increasing responsibility, most recently serving from 2009-2016 as Noven's president, chief executive officer and as a member of its board of directors. Mr. Eisenberg previously served as an independent director for Mabvax Therapeutics Holdings, Inc. from February 2016 until his resignation in July 2018. Mr. Eisenberg obtained his J.D. at Columbia University Law School and a B.S. in Economics from the Wharton School, University of Pennsylvania.
- Dmitry Genkin
-
Dmitry Genkin于2017年8月14日被任命为董事会成员。Genkin博士此前曾于2004年至2016年在公司董事会任职。1992年至1993年，他在伦敦大学药学院Gregory Gregoriadis教授指导下学习药物输送，1992年至1993年在斯德哥尔摩卡罗林斯卡医院临床药理系学习。Genkin自2005年起担任PJSC Pharmsynthez（一家上市公司，Xenetic重要股东）执行董事长。在此之前，Genkin博士领导了许多俄罗斯最大的制药公司，包括Pharmavit，俄罗斯制药市场的大型参与者。1998年，他被俄罗斯自然科学学院授予银质奖章。
Dmitry Genkin,previously served on the Company's Board of Directors from 2017-2021. He has the Russian equivalent of an MD in Internal Therapy and studied drug delivery under Professor Gregory Gregoriadis at The School of Pharmacy, University of London in 1992, as well as the Department of Clinical Pharmacology at Karolinska Hospital, Stockholm from 1992 until 1993. Since 2005, Dr. Genkin has served as Executive Chairman of PJSC Pharmsynthez, a public company and a significant stockholder of Xenetic. Dr. Genkin is founder and Board member of Santersus AG – a Swiss private pharmaceutical company developing novel apheresis therapies for unmet medical need indications. Dr. Genkin is on the board of CLS Therapeutics Inc. and Peri-Ness Ltd. – private biotechnology companies developing anti-NETosis therapies. Prior to 2005, Dr. Genkin headed a number of Russia's largest pharmaceutical companies including Pharmavit, a large player in the Russian pharmaceutical market. In 1998, he was awarded the silver medal by the Russian Natural Science Academy. - Dmitry Genkin于2017年8月14日被任命为董事会成员。Genkin博士此前曾于2004年至2016年在公司董事会任职。1992年至1993年，他在伦敦大学药学院Gregory Gregoriadis教授指导下学习药物输送，1992年至1993年在斯德哥尔摩卡罗林斯卡医院临床药理系学习。Genkin自2005年起担任PJSC Pharmsynthez（一家上市公司，Xenetic重要股东）执行董事长。在此之前，Genkin博士领导了许多俄罗斯最大的制药公司，包括Pharmavit，俄罗斯制药市场的大型参与者。1998年，他被俄罗斯自然科学学院授予银质奖章。
- Dmitry Genkin,previously served on the Company's Board of Directors from 2017-2021. He has the Russian equivalent of an MD in Internal Therapy and studied drug delivery under Professor Gregory Gregoriadis at The School of Pharmacy, University of London in 1992, as well as the Department of Clinical Pharmacology at Karolinska Hospital, Stockholm from 1992 until 1993. Since 2005, Dr. Genkin has served as Executive Chairman of PJSC Pharmsynthez, a public company and a significant stockholder of Xenetic. Dr. Genkin is founder and Board member of Santersus AG – a Swiss private pharmaceutical company developing novel apheresis therapies for unmet medical need indications. Dr. Genkin is on the board of CLS Therapeutics Inc. and Peri-Ness Ltd. – private biotechnology companies developing anti-NETosis therapies. Prior to 2005, Dr. Genkin headed a number of Russia's largest pharmaceutical companies including Pharmavit, a large player in the Russian pharmaceutical market. In 1998, he was awarded the silver medal by the Russian Natural Science Academy.
- Moshe Mizrahy
-
Moshe Mizrahy于2008年共同创立了该公司，自成立以来一直担任我们的首席执行官兼董事会主席。在此之前，Mizrahy先生是Syneron MedicalLtd.公司（一家位于以色列的医疗美容设备公司）的联合创始人兼首席执行官。Mizrahy先生也是Home Skinovations Ltd.的前首席执行官，该公司是一家活跃于家庭使用市场的国际医疗美容消费设备公司，目前自2007年起担任其董事会主席。除Home Skinovations Ltd.外，Mizrahy先生目前担任以下公司的董事会成员:Sipnose Ltd.、Pet Novations Ltd.、Peri-ness Technologies Ltd.、Easy-Lap Ltd、O.B.-Tools Ltd.、Urifer Ltd.、Easy Notes Ltd.、Escape Rescue Systems Ltd.、New Forest Wood Products-2012Ltd.，M.N.Business Strategy Ltd.、Himalaya Family Office Advisory Ltd.和Polimer Logistics Israel Ltd.Mizrahy先生在特拉维夫大学（Tel Aviv University）获得工程学学士学位，并在纽约佩斯大学（Pace University）获得工商管理硕士学位。
Moshe Mizrahy,is co-founder of InMode Ltd. (NASDAQ: INMD) and has served as its Chief Executive Officer and Chairman of its board of directors since its inception in 2008. Prior to that, Mr. Mizrahy was co-founder and chief executive officer of Syneron Medical Ltd. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd., and is currently chairman of its board. In addition to Home Skinovations Ltd., Mr. Mizrahy currently sits on the board of directors of SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Santersus AG, Easy-Lap Ltd., O.B.-Tools Ltd., Urifer Ltd., Easy Notes Ltd., Escape Rescue Systems Ltd., M.N. Business Strategy Ltd., Silk'n Cure Ltd., Himalaya Family Office Advising Ltd. and Polimer Logistics (Israel) Ltd. Mr. Mizrahy is co-founder and general partner of Nitzanim AVX Kyocera Venture Capital Fund and First Israel Mezzeine Investors Fund. Mr. Mizrahy has expertise in value creation for medical technologies, fundraising, public offerings, marketing and regulatory affairs. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York. - Moshe Mizrahy于2008年共同创立了该公司，自成立以来一直担任我们的首席执行官兼董事会主席。在此之前，Mizrahy先生是Syneron MedicalLtd.公司（一家位于以色列的医疗美容设备公司）的联合创始人兼首席执行官。Mizrahy先生也是Home Skinovations Ltd.的前首席执行官，该公司是一家活跃于家庭使用市场的国际医疗美容消费设备公司，目前自2007年起担任其董事会主席。除Home Skinovations Ltd.外，Mizrahy先生目前担任以下公司的董事会成员:Sipnose Ltd.、Pet Novations Ltd.、Peri-ness Technologies Ltd.、Easy-Lap Ltd、O.B.-Tools Ltd.、Urifer Ltd.、Easy Notes Ltd.、Escape Rescue Systems Ltd.、New Forest Wood Products-2012Ltd.，M.N.Business Strategy Ltd.、Himalaya Family Office Advisory Ltd.和Polimer Logistics Israel Ltd.Mizrahy先生在特拉维夫大学（Tel Aviv University）获得工程学学士学位，并在纽约佩斯大学（Pace University）获得工商管理硕士学位。
- Moshe Mizrahy,is co-founder of InMode Ltd. (NASDAQ: INMD) and has served as its Chief Executive Officer and Chairman of its board of directors since its inception in 2008. Prior to that, Mr. Mizrahy was co-founder and chief executive officer of Syneron Medical Ltd. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd., and is currently chairman of its board. In addition to Home Skinovations Ltd., Mr. Mizrahy currently sits on the board of directors of SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Santersus AG, Easy-Lap Ltd., O.B.-Tools Ltd., Urifer Ltd., Easy Notes Ltd., Escape Rescue Systems Ltd., M.N. Business Strategy Ltd., Silk'n Cure Ltd., Himalaya Family Office Advising Ltd. and Polimer Logistics (Israel) Ltd. Mr. Mizrahy is co-founder and general partner of Nitzanim AVX Kyocera Venture Capital Fund and First Israel Mezzeine Investors Fund. Mr. Mizrahy has expertise in value creation for medical technologies, fundraising, public offerings, marketing and regulatory affairs. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York.
- Grigory Borisenko
-
Grigory Borisenko于2019年9月被任命为董事会成员。Borisenko先生是Rusnano Management Company LLC的投资总监，这是一家俄罗斯的风险投资&私募股权管理公司。Borisenko先生在生命科学领域拥有超过20年的科学、管理和战略经验。Borisenko先生自2012年以来一直专注于生命科学的投资项目，从2009年到2012年，他是the State Corporation，Rusnano科学和技术部的制药部门主管。Borisenko先生目前在两家生物技术公司ATEA Pharmaceuticals，Inc.和Adastra Pharmaceuticals，Inc.的董事会任职，并于2011年至2014年在NearMedic Pharm LLC的董事会任职。在他的投资生涯之前，Borisenko先生在匹兹堡大学（University of Pittsburgh），俄罗斯国立医科大学（Russian State Medical University）和医学生物问题研究所（Institute of Medico-Biological Problems）担任学术职务。他在领先的生物化学和细胞生物学期刊上共同撰写了50多篇同行评议的出版物。Borisenko先生在俄罗斯国立医科大学（Russian State Medical University）获得硕士学位和博士学位，并且是Fogarty International和NIH的国际奖学金获得者。
Grigory Borisenko,was appointed to the Board in September 2019. Dr. Borisenko has over 20 years of scientific, management and strategic experience in the life science field. Since April 2022, Dr. Borisenko has been an independent consultant for a number of companies. Prior to that time, Dr. Borisenko served as an Investment Director of RUSNANO Management Company LLC, a venture capital & private equity management company in Russia, and has specialized in investment projects in life sciences from 2012 through March 31, 2022. Dr. Borisenko has served on the board of directors of Atea Pharmaceuticals, Inc., Adastra Pharmaceuticals, Inc., Nearmedic Pharm LLC, Novamedica LLC and RusnanoMedInvest LLC. Prior to his investment career, Dr. Borisenko held academic appointments with the University of Pittsburgh, Russian State Medical University and Institute of Medico-Biological Problems. He has co-authored over fifty peer-reviewed publications in leading biochemistry and cell biology journals. Dr. Borisenko received his M.S. and Ph.D. from the Russian State Medical University, and is a recipient of Fogarty International and International Fellowship Awards from NIH. - Grigory Borisenko于2019年9月被任命为董事会成员。Borisenko先生是Rusnano Management Company LLC的投资总监，这是一家俄罗斯的风险投资&私募股权管理公司。Borisenko先生在生命科学领域拥有超过20年的科学、管理和战略经验。Borisenko先生自2012年以来一直专注于生命科学的投资项目，从2009年到2012年，他是the State Corporation，Rusnano科学和技术部的制药部门主管。Borisenko先生目前在两家生物技术公司ATEA Pharmaceuticals，Inc.和Adastra Pharmaceuticals，Inc.的董事会任职，并于2011年至2014年在NearMedic Pharm LLC的董事会任职。在他的投资生涯之前，Borisenko先生在匹兹堡大学（University of Pittsburgh），俄罗斯国立医科大学（Russian State Medical University）和医学生物问题研究所（Institute of Medico-Biological Problems）担任学术职务。他在领先的生物化学和细胞生物学期刊上共同撰写了50多篇同行评议的出版物。Borisenko先生在俄罗斯国立医科大学（Russian State Medical University）获得硕士学位和博士学位，并且是Fogarty International和NIH的国际奖学金获得者。
- Grigory Borisenko,was appointed to the Board in September 2019. Dr. Borisenko has over 20 years of scientific, management and strategic experience in the life science field. Since April 2022, Dr. Borisenko has been an independent consultant for a number of companies. Prior to that time, Dr. Borisenko served as an Investment Director of RUSNANO Management Company LLC, a venture capital & private equity management company in Russia, and has specialized in investment projects in life sciences from 2012 through March 31, 2022. Dr. Borisenko has served on the board of directors of Atea Pharmaceuticals, Inc., Adastra Pharmaceuticals, Inc., Nearmedic Pharm LLC, Novamedica LLC and RusnanoMedInvest LLC. Prior to his investment career, Dr. Borisenko held academic appointments with the University of Pittsburgh, Russian State Medical University and Institute of Medico-Biological Problems. He has co-authored over fifty peer-reviewed publications in leading biochemistry and cell biology journals. Dr. Borisenko received his M.S. and Ph.D. from the Russian State Medical University, and is a recipient of Fogarty International and International Fellowship Awards from NIH.
- James Callaway
-
James Callaway于2017年8月14日被任命为董事会成员。Callaway博士在执行BioTherapeutics公司的产品开发业务方面拥有30多年的经验，目前担任Kalgene Pharmaceuticals公司的独立董事。Callaway博士是风险投资支持的生物技术社区中经验丰富的首席执行官，在他的职业生涯中，他建立并运营了多家公司，从研究公司转变为临床阶段的运营实体。他也担任Callaway Innovations公司的生物技术社区的公司战略顾问。Callaway博士曾担任私人持有的生物技术公司的首席执行官，包括专注于老年痴呆症疾病治疗的Kalgene公司，BBB运输公司Armagen，Inc.和糖尿病神经病变公司Cebix，Inc.。在这些努力之前，Callaway博士在Elan Pharmaceuticals担任多个高级领导职位，包括同时担任开发主管并监督与Wyeth Pharmaceuticals在Alzheimer’；s疾病免疫治疗计划中的复杂合作伙伴关系。在过去的二十年中，他为广泛的治疗应用开发抗体，包括多发性硬化症（Tysabri®；:药物开发），阿尔茨海默氏症（Bapineuzumab:项目执行官）和血脑屏障运输的治疗，并与美国食品和药物管理局合作多个孤儿药开发项目。
James Callaway,was appointed to the Board on August 14, 2017. Dr. Callaway has over 30 years of experience in the execution of product development operations for biotherapeutics and currently serves as an independent board member of KalGene Pharmaceuticals ("KalGene") and Nuravax. Dr. Callaway is a seasoned CEO within the venture-backed biotech community and over the course of his career he has built and operated several companies, transforming each from research companies to clinical stage operating entities. He also serves as a Corporate Strategy Consultant to the biotech community at Callaway Innovations. Dr. Callaway has served as CEO of privately-held biotech companies including KalGene, a company focused on disease-modifying therapies in Alzheimer's Disease, ArmaGen, Inc., a BBB transport company, and CEBIX, Inc., a diabetic neuropathy company. Prior to these efforts, Dr. Callaway held multiple senior leadership positions at Elan Pharmaceuticals, including simultaneously acting as Head of Development and overseeing the complex partnership with Wyeth Pharmaceuticals in the Alzheimer's disease immunotherapy program. He has developed antibodies for a wide-range of therapeutic applications over the past two decades, including treatments of multiple sclerosis (Tysabri: pharmaceutical development), Alzheimer's disease (bapineuzumab: Program Executive), and blood brain barrier transport, and has worked with the United States Food and Drug Administration on multiple orphan drug development programs. - James Callaway于2017年8月14日被任命为董事会成员。Callaway博士在执行BioTherapeutics公司的产品开发业务方面拥有30多年的经验，目前担任Kalgene Pharmaceuticals公司的独立董事。Callaway博士是风险投资支持的生物技术社区中经验丰富的首席执行官，在他的职业生涯中，他建立并运营了多家公司，从研究公司转变为临床阶段的运营实体。他也担任Callaway Innovations公司的生物技术社区的公司战略顾问。Callaway博士曾担任私人持有的生物技术公司的首席执行官，包括专注于老年痴呆症疾病治疗的Kalgene公司，BBB运输公司Armagen，Inc.和糖尿病神经病变公司Cebix，Inc.。在这些努力之前，Callaway博士在Elan Pharmaceuticals担任多个高级领导职位，包括同时担任开发主管并监督与Wyeth Pharmaceuticals在Alzheimer’；s疾病免疫治疗计划中的复杂合作伙伴关系。在过去的二十年中，他为广泛的治疗应用开发抗体，包括多发性硬化症（Tysabri®；:药物开发），阿尔茨海默氏症（Bapineuzumab:项目执行官）和血脑屏障运输的治疗，并与美国食品和药物管理局合作多个孤儿药开发项目。
- James Callaway,was appointed to the Board on August 14, 2017. Dr. Callaway has over 30 years of experience in the execution of product development operations for biotherapeutics and currently serves as an independent board member of KalGene Pharmaceuticals ("KalGene") and Nuravax. Dr. Callaway is a seasoned CEO within the venture-backed biotech community and over the course of his career he has built and operated several companies, transforming each from research companies to clinical stage operating entities. He also serves as a Corporate Strategy Consultant to the biotech community at Callaway Innovations. Dr. Callaway has served as CEO of privately-held biotech companies including KalGene, a company focused on disease-modifying therapies in Alzheimer's Disease, ArmaGen, Inc., a BBB transport company, and CEBIX, Inc., a diabetic neuropathy company. Prior to these efforts, Dr. Callaway held multiple senior leadership positions at Elan Pharmaceuticals, including simultaneously acting as Head of Development and overseeing the complex partnership with Wyeth Pharmaceuticals in the Alzheimer's disease immunotherapy program. He has developed antibodies for a wide-range of therapeutic applications over the past two decades, including treatments of multiple sclerosis (Tysabri: pharmaceutical development), Alzheimer's disease (bapineuzumab: Program Executive), and blood brain barrier transport, and has worked with the United States Food and Drug Administration on multiple orphan drug development programs.
- Alexey Vinogradov
-
Alexey Vinogradov自2019年7月起担任董事会成员。Vinogradov博士目前担任Cantreva LLC的业务开发总监兼运营总监，该公司是一家俄罗斯公司，具有在可再生能源太阳能，风能，水力发电领域提供服务的丰富专业经验，自2017年9月起在交钥匙基础上进行工作。Vinogradov博士此前于2015年5月至2017年5月担任阿联酋迪拜Togas Middle East LLC的总经理。在此之前，Vinogradov博士于2012年3月至2016年11月担任俄罗斯Togas Group LLC的分公司经理。
Alexey Vinogradov,has served as a member of Xenetic Biosciences, Inc. Board since July 2019. Mr. Vinogradov currently works as Business Development Manager at Mag. Peter G. Wahl's Law Firm in Vienna, Austria, which main focus is on corporate, property and commercial law. Mr. Vinogradov previously acted as Business Development Director and Operations Director at Cantreva LLC, a Russian company with extensive specialized experience of delivering services in the field of renewable energy (solar, wind, hydro power), performing works on a "turnkey" basis from September 2017 to 2022. Mr. Vinogradov previously served as General Manager at Togas Middle East LLC in Dubai, UAE from May 2015 to May 2017. Prior to that, Mr. Vinogradov served as branch manager at Togas Group LLC in Russia from March 2012 to November 2016. - Alexey Vinogradov自2019年7月起担任董事会成员。Vinogradov博士目前担任Cantreva LLC的业务开发总监兼运营总监，该公司是一家俄罗斯公司，具有在可再生能源太阳能，风能，水力发电领域提供服务的丰富专业经验，自2017年9月起在交钥匙基础上进行工作。Vinogradov博士此前于2015年5月至2017年5月担任阿联酋迪拜Togas Middle East LLC的总经理。在此之前，Vinogradov博士于2012年3月至2016年11月担任俄罗斯Togas Group LLC的分公司经理。
- Alexey Vinogradov,has served as a member of Xenetic Biosciences, Inc. Board since July 2019. Mr. Vinogradov currently works as Business Development Manager at Mag. Peter G. Wahl's Law Firm in Vienna, Austria, which main focus is on corporate, property and commercial law. Mr. Vinogradov previously acted as Business Development Director and Operations Director at Cantreva LLC, a Russian company with extensive specialized experience of delivering services in the field of renewable energy (solar, wind, hydro power), performing works on a "turnkey" basis from September 2017 to 2022. Mr. Vinogradov previously served as General Manager at Togas Middle East LLC in Dubai, UAE from May 2015 to May 2017. Prior to that, Mr. Vinogradov served as branch manager at Togas Group LLC in Russia from March 2012 to November 2016.
- Moshe Mizrahy
-
Moshe Mizrahy是InMode Ltd.（纳斯达克股票代码：INMD）的联合创始人，自2008年成立以来一直担任其首席执行官和董事会主席。在此之前，Mizrahy先生是Syneron Medical Ltd.的联合创始人和首席执行官。Mizrahy先生也是Home Skinovations Ltd.的前首席执行官，目前是该公司的董事会主席。除Home Skinovations Ltd.外，Mizrahy先生目前是SipNose Ltd.、Pet Novations Ltd.、Peri-Ness Technologies Ltd.、Santersus AG、Easy-Lap Ltd.、O.B.-Tools Ltd.、Urifer Ltd.、Easy Notes Ltd.、Escape Rescue Systems Ltd.、MN. Business Strategy Ltd.、Silkien Cure Ltd.、Himalaya Family Office Advising Ltd.和Polimer Logistics（Israel）Ltd.的董事。Mizrahy先生是Nitzanim AVX Kyocera Venture Capital Fund和First Israel Mezzeine Investors Fund的联合创始人和普通合伙人。Mizrahy先生在医疗技术的价值创造、筹资、公开发行、营销和监管事务方面拥有专长。米兹拉希拥有特拉维夫大学的工程学学士学位和纽约佩斯大学的MBA学位。
Moshe Mizrahy,is co-founder of InMode Ltd. (NASDAQ: INMD) and has served as its Chief Executive Officer and Chairman of its board of directors since its inception in 2008. Prior to that, Mr. Mizrahy was co-founder and chief executive officer of Syneron Medical Ltd. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd., and is currently chairman of its board. In addition to Home Skinovations Ltd., Mr. Mizrahy currently sits on the board of directors of SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Santersus AG, Easy-Lap Ltd., O.B.-Tools Ltd., Urifer Ltd., Easy Notes Ltd., Escape Rescue Systems Ltd., M.N. Business Strategy Ltd., Silk'n Cure Ltd., Himalaya Family Office Advising Ltd. and Polimer Logistics (Israel) Ltd. Mr. Mizrahy is co-founder and general partner of Nitzanim AVX Kyocera Venture Capital Fund and First Israel Mezzeine Investors Fund. Mr. Mizrahy has expertise in value creation for medical technologies, fundraising, public offerings, marketing and regulatory affairs. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York. - Moshe Mizrahy是InMode Ltd.（纳斯达克股票代码：INMD）的联合创始人，自2008年成立以来一直担任其首席执行官和董事会主席。在此之前，Mizrahy先生是Syneron Medical Ltd.的联合创始人和首席执行官。Mizrahy先生也是Home Skinovations Ltd.的前首席执行官，目前是该公司的董事会主席。除Home Skinovations Ltd.外，Mizrahy先生目前是SipNose Ltd.、Pet Novations Ltd.、Peri-Ness Technologies Ltd.、Santersus AG、Easy-Lap Ltd.、O.B.-Tools Ltd.、Urifer Ltd.、Easy Notes Ltd.、Escape Rescue Systems Ltd.、MN. Business Strategy Ltd.、Silkien Cure Ltd.、Himalaya Family Office Advising Ltd.和Polimer Logistics（Israel）Ltd.的董事。Mizrahy先生是Nitzanim AVX Kyocera Venture Capital Fund和First Israel Mezzeine Investors Fund的联合创始人和普通合伙人。Mizrahy先生在医疗技术的价值创造、筹资、公开发行、营销和监管事务方面拥有专长。米兹拉希拥有特拉维夫大学的工程学学士学位和纽约佩斯大学的MBA学位。
- Moshe Mizrahy,is co-founder of InMode Ltd. (NASDAQ: INMD) and has served as its Chief Executive Officer and Chairman of its board of directors since its inception in 2008. Prior to that, Mr. Mizrahy was co-founder and chief executive officer of Syneron Medical Ltd. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd., and is currently chairman of its board. In addition to Home Skinovations Ltd., Mr. Mizrahy currently sits on the board of directors of SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Santersus AG, Easy-Lap Ltd., O.B.-Tools Ltd., Urifer Ltd., Easy Notes Ltd., Escape Rescue Systems Ltd., M.N. Business Strategy Ltd., Silk'n Cure Ltd., Himalaya Family Office Advising Ltd. and Polimer Logistics (Israel) Ltd. Mr. Mizrahy is co-founder and general partner of Nitzanim AVX Kyocera Venture Capital Fund and First Israel Mezzeine Investors Fund. Mr. Mizrahy has expertise in value creation for medical technologies, fundraising, public offerings, marketing and regulatory affairs. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York.
- Adam Logal
-
Adam Logal ，他担任OPKO公司的副总裁和首席财务官（2014年4月以来），以及OPKO公司的财务副总裁、首席财务官和司库（2007年3月以来）。从2002年到2007年，他担任Nabi Biopharmaceuticals公司（公开交易，生物制药公司，从事自营产品的开发和商业化）的高级管理人员。他曾任职Nabi Biopharmaceuticals公司，并不断被提拔，最终担任高级主管，负责会计和报告。
Adam Logal,has served as OPKO's Senior Vice President, Chief Financial Officer, Chief Accounting Officer, and Treasurer since March 2014, Vice President of Finance, Chief Accounting Officer and Treasurer from July 2012 until March 2014, and Director of Finance, Chief Accounting Officer and Treasurer from March 2007 until July 2012. In addition, Mr. Logal also served as President of GeneDx, a subsidiary of OPKO, from July 2020 to June 2021. He currently serves as chairman of the board of directors of Xenetics Biosciences, Inc. (NASDAQ CM:XBIO), a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. He previously served on the board of directors of VBI Vaccines, Inc. (NASDAQ:VBIV) from April 2014 until 2018. From 2002 to 2007, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting. - Adam Logal ，他担任OPKO公司的副总裁和首席财务官（2014年4月以来），以及OPKO公司的财务副总裁、首席财务官和司库（2007年3月以来）。从2002年到2007年，他担任Nabi Biopharmaceuticals公司（公开交易，生物制药公司，从事自营产品的开发和商业化）的高级管理人员。他曾任职Nabi Biopharmaceuticals公司，并不断被提拔，最终担任高级主管，负责会计和报告。
- Adam Logal,has served as OPKO's Senior Vice President, Chief Financial Officer, Chief Accounting Officer, and Treasurer since March 2014, Vice President of Finance, Chief Accounting Officer and Treasurer from July 2012 until March 2014, and Director of Finance, Chief Accounting Officer and Treasurer from March 2007 until July 2012. In addition, Mr. Logal also served as President of GeneDx, a subsidiary of OPKO, from July 2020 to June 2021. He currently serves as chairman of the board of directors of Xenetics Biosciences, Inc. (NASDAQ CM:XBIO), a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. He previously served on the board of directors of VBI Vaccines, Inc. (NASDAQ:VBIV) from April 2014 until 2018. From 2002 to 2007, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting.
高管简历
中英对照 | 中文 | 英文- Jeffrey F. Eisenberg
Jeffrey F. Eisenberg自2016年12月2日起担任首席运营官，于2017年10月26日被任命为Xenetic Biosciences, Inc.首席执行官，并自2016年7月起担任Xenetic Biosciences, Inc.董事会成员。Eisenberg先生以前曾在久光制药公司的子公司诺文制药公司（“诺文”）工作，在那里他担任过越来越多的职务，最近在2009-2016年期间担任诺文公司总裁、首席执行官和董事会成员。Eisenberg先生此前于2016年2月起担任Mabvax Therapeutics Holdings独立董事，至2018年7月辞职。Eisenberg先生在哥伦比亚大学法学院获得法学博士学位，在宾夕法尼亚大学沃顿商学院获得经济学学士学位。
Jeffrey F. Eisenberg,was appointed Xenetic Biosciences, Inc. Chief Executive Officer on October 26, 2017, after serving as Chief Operating Officer since December 2, 2016, and has served as a member of Xenetic Biosciences, Inc. Board since July 2016. Mr. Eisenberg previously worked at Noven Pharmaceuticals, Inc. ("Noven"), a subsidiary of Hisamitsu Pharmaceutical, Inc., where he held various positions of increasing responsibility, most recently serving from 2009-2016 as Noven's president, chief executive officer and as a member of its board of directors. Mr. Eisenberg previously served as an independent director for Mabvax Therapeutics Holdings, Inc. from February 2016 until his resignation in July 2018. Mr. Eisenberg obtained his J.D. at Columbia University Law School and a B.S. in Economics from the Wharton School, University of Pennsylvania.- Jeffrey F. Eisenberg自2016年12月2日起担任首席运营官，于2017年10月26日被任命为Xenetic Biosciences, Inc.首席执行官，并自2016年7月起担任Xenetic Biosciences, Inc.董事会成员。Eisenberg先生以前曾在久光制药公司的子公司诺文制药公司（“诺文”）工作，在那里他担任过越来越多的职务，最近在2009-2016年期间担任诺文公司总裁、首席执行官和董事会成员。Eisenberg先生此前于2016年2月起担任Mabvax Therapeutics Holdings独立董事，至2018年7月辞职。Eisenberg先生在哥伦比亚大学法学院获得法学博士学位，在宾夕法尼亚大学沃顿商学院获得经济学学士学位。
- Jeffrey F. Eisenberg,was appointed Xenetic Biosciences, Inc. Chief Executive Officer on October 26, 2017, after serving as Chief Operating Officer since December 2, 2016, and has served as a member of Xenetic Biosciences, Inc. Board since July 2016. Mr. Eisenberg previously worked at Noven Pharmaceuticals, Inc. ("Noven"), a subsidiary of Hisamitsu Pharmaceutical, Inc., where he held various positions of increasing responsibility, most recently serving from 2009-2016 as Noven's president, chief executive officer and as a member of its board of directors. Mr. Eisenberg previously served as an independent director for Mabvax Therapeutics Holdings, Inc. from February 2016 until his resignation in July 2018. Mr. Eisenberg obtained his J.D. at Columbia University Law School and a B.S. in Economics from the Wharton School, University of Pennsylvania.
- Curtis Lockshin
Curtis Lockshin最初于2014年3月以兼职身份加入我们，担任研究与运营Vice President，并于2017年1月1日被任命为我们的首席科学官。Lockshin博士在开发和商业阶段生物技术公司担任过几个管理职位，拥有发现、临床前和临床开发以及商业制造方面的经验。2013年5月起，他担任Guardum Pharmaceuticals LLC“；Guardum”；的总裁、首席执行官，这是本公司控股股东PJSC Pharmsynthez的全资子公司，除此之外，他还继续担任该职位。Lockshin博士没有获得这些服务的薪水，但确实获得了医疗福利，并在Guardum&8217；s健康计划下涵盖至2018年7月31日。此外，Lockshin博士还兼职担任多家生物技术公司的高级管理人员或顾问，包括在多起合并后担任一系列相关公司的高级管理人员，最初担任Scivac Therapeutics，Inc.及其子公司Scivac，Ltd.的首席执行官兼董事，从2014年9月到2016年7月。Scivac Therapeutics，Inc.于2016年7月与VBI Vaccines，Inc.合并后，Lockshin博士担任合并后公司的首席技术官，直到2016年12月。他目前担任Phio Pharmaceuticals Corporation（上市临床阶段RNAi公司，专注于免疫肿瘤学）的董事会成员（2013年4月以来）。Lockshin博士在麻省理工学院（Massachusetts Institute of Technology）获得生命科学学士学位和生物化学博士学位。自2004年4月以来，Lockshin博士还担任Ruth K.Broad Biomedical Research Foundation的董事会成员，这是一家杜克大学支持公司，通过校内，校外和国际赠款支持与阿尔茨海默氏症和神经退行性变有关的基础研究。
Curtis Lockshin,initially joined Xenetic Biosciences, Inc. on a part-time basis in March 2014 as Xenetic Biosciences, Inc. Vice President of Research & Operations and was appointed Xenetic Biosciences, Inc. Chief Scientific Officer effective January 1, 2017. Dr. Lockshin has held several management positions at development and commercial stage biotechnology companies, with experience including discovery, preclinical and clinical development, as well as commercial manufacturing. Since May 2013, he has held the position of president and chief executive officer of Guardum Pharmaceuticals LLC ("Guardum"), a wholly owned subsidiary of PJSC Pharmsynthez, a position which he continues to hold in addition to his position with Xenetic Biosciences, Inc. . Dr. Lockshin does not receive a salary for these services but did receive medical benefits and was covered under Guardum's health plan through July 31, 2018. In addition, Dr. Lockshin has served as an officer or consultant of several biotechnology companies on a part-time basis, including as an officer of a series of related companies following multiple mergers beginning as chief executive officer and director of SciVac Therapeutics, Inc. and its subsidiary SciVac, Ltd., from September 2014 until July 2016. After SciVac Therapeutics, Inc.'s merger with VBI Vaccines, Inc. in July 2016, Dr. Lockshin served as chief technical officer of the merged company until December 2016. Dr. Lockshin is currently serving as a member of the board of directors of Phio Pharmaceuticals Corporation, a publicly traded clinical-stage RNAi company focused on immune-oncology, a position he has held since April 2013. Dr. Lockshin has an S.B. in Life Sciences and a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology. Since April 2004, Dr. Lockshin has also served as a member of the board of directors of the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation that supports basic research related to Alzheimer's disease and neurodegeneration via intramural, extramural and international grants.- Curtis Lockshin最初于2014年3月以兼职身份加入我们，担任研究与运营Vice President，并于2017年1月1日被任命为我们的首席科学官。Lockshin博士在开发和商业阶段生物技术公司担任过几个管理职位，拥有发现、临床前和临床开发以及商业制造方面的经验。2013年5月起，他担任Guardum Pharmaceuticals LLC“；Guardum”；的总裁、首席执行官，这是本公司控股股东PJSC Pharmsynthez的全资子公司，除此之外，他还继续担任该职位。Lockshin博士没有获得这些服务的薪水，但确实获得了医疗福利，并在Guardum&8217；s健康计划下涵盖至2018年7月31日。此外，Lockshin博士还兼职担任多家生物技术公司的高级管理人员或顾问，包括在多起合并后担任一系列相关公司的高级管理人员，最初担任Scivac Therapeutics，Inc.及其子公司Scivac，Ltd.的首席执行官兼董事，从2014年9月到2016年7月。Scivac Therapeutics，Inc.于2016年7月与VBI Vaccines，Inc.合并后，Lockshin博士担任合并后公司的首席技术官，直到2016年12月。他目前担任Phio Pharmaceuticals Corporation（上市临床阶段RNAi公司，专注于免疫肿瘤学）的董事会成员（2013年4月以来）。Lockshin博士在麻省理工学院（Massachusetts Institute of Technology）获得生命科学学士学位和生物化学博士学位。自2004年4月以来，Lockshin博士还担任Ruth K.Broad Biomedical Research Foundation的董事会成员，这是一家杜克大学支持公司，通过校内，校外和国际赠款支持与阿尔茨海默氏症和神经退行性变有关的基础研究。
- Curtis Lockshin,initially joined Xenetic Biosciences, Inc. on a part-time basis in March 2014 as Xenetic Biosciences, Inc. Vice President of Research & Operations and was appointed Xenetic Biosciences, Inc. Chief Scientific Officer effective January 1, 2017. Dr. Lockshin has held several management positions at development and commercial stage biotechnology companies, with experience including discovery, preclinical and clinical development, as well as commercial manufacturing. Since May 2013, he has held the position of president and chief executive officer of Guardum Pharmaceuticals LLC ("Guardum"), a wholly owned subsidiary of PJSC Pharmsynthez, a position which he continues to hold in addition to his position with Xenetic Biosciences, Inc. . Dr. Lockshin does not receive a salary for these services but did receive medical benefits and was covered under Guardum's health plan through July 31, 2018. In addition, Dr. Lockshin has served as an officer or consultant of several biotechnology companies on a part-time basis, including as an officer of a series of related companies following multiple mergers beginning as chief executive officer and director of SciVac Therapeutics, Inc. and its subsidiary SciVac, Ltd., from September 2014 until July 2016. After SciVac Therapeutics, Inc.'s merger with VBI Vaccines, Inc. in July 2016, Dr. Lockshin served as chief technical officer of the merged company until December 2016. Dr. Lockshin is currently serving as a member of the board of directors of Phio Pharmaceuticals Corporation, a publicly traded clinical-stage RNAi company focused on immune-oncology, a position he has held since April 2013. Dr. Lockshin has an S.B. in Life Sciences and a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology. Since April 2004, Dr. Lockshin has also served as a member of the board of directors of the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation that supports basic research related to Alzheimer's disease and neurodegeneration via intramural, extramural and international grants.
- James Parslow
James Parslow于2017年4月3日，被任命为Xenetic Biosciences, Inc.首席财务官。Parslow先生最近于2006年担任World Energy Solutions，Inc.的首席财务官、财务主管兼秘书，该公司是一家公开上市的企业对企业电子商务公司，从事能源和环境商品经纪业务，直至2015年被EnerNOC，Inc.收购。从2015年到2017年，他担任独立顾问，为多家新兴科技公司提供临时首席财务官服务。Parslow先生是一名注册会计师，在生物技术、清洁技术、电子商务和高科技制造行业为私营和上市公司服务超过35年。他拥有圣十字学院经济学和会计学学士学位和本特利大学金融学硕士学位。
James Parslow,was appointed Xenetic Biosciences, Inc. Chief Financial Officer on April 3, 2017. Mr. Parslow most recently served as Chief Financial Officer, Treasurer and Secretary of World Energy Solutions, Inc., a publicly-traded business-to-business e-commerce company brokering energy and environmental commodities, from 2006 until its acquisition by EnerNOC, Inc. in 2015. From 2015 until 2017, he served as an independent consultant providing interim chief financial officer services to multiple emerging technology companies. Mr. Parslow is a Certified Public Accountant with over 35 years of experience serving private and public companies in the biotech, clean tech, e-commerce, and high-tech manufacturing industries. He holds an A.B. in Economics and Accounting from the College of the Holy Cross and an M.B.A. with a concentration in Finance from Bentley University.- James Parslow于2017年4月3日，被任命为Xenetic Biosciences, Inc.首席财务官。Parslow先生最近于2006年担任World Energy Solutions，Inc.的首席财务官、财务主管兼秘书，该公司是一家公开上市的企业对企业电子商务公司，从事能源和环境商品经纪业务，直至2015年被EnerNOC，Inc.收购。从2015年到2017年，他担任独立顾问，为多家新兴科技公司提供临时首席财务官服务。Parslow先生是一名注册会计师，在生物技术、清洁技术、电子商务和高科技制造行业为私营和上市公司服务超过35年。他拥有圣十字学院经济学和会计学学士学位和本特利大学金融学硕士学位。
- James Parslow,was appointed Xenetic Biosciences, Inc. Chief Financial Officer on April 3, 2017. Mr. Parslow most recently served as Chief Financial Officer, Treasurer and Secretary of World Energy Solutions, Inc., a publicly-traded business-to-business e-commerce company brokering energy and environmental commodities, from 2006 until its acquisition by EnerNOC, Inc. in 2015. From 2015 until 2017, he served as an independent consultant providing interim chief financial officer services to multiple emerging technology companies. Mr. Parslow is a Certified Public Accountant with over 35 years of experience serving private and public companies in the biotech, clean tech, e-commerce, and high-tech manufacturing industries. He holds an A.B. in Economics and Accounting from the College of the Holy Cross and an M.B.A. with a concentration in Finance from Bentley University.